Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have received a consensus rating of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $18.89.

TEVA has been the subject of several recent analyst reports. Piper Sandler reissued an “overweight” rating and set a $20.00 price objective (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. Barclays increased their price target on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Wednesday, July 10th. Finally, Jefferies Financial Group lifted their target price on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, June 27th.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $17.80 on Tuesday. The company has a 50 day moving average price of $17.42 and a two-hundred day moving average price of $15.78. Teva Pharmaceutical Industries has a 12-month low of $8.06 and a 12-month high of $19.08. The stock has a market capitalization of $20.17 billion, a PE ratio of -43.41, a price-to-earnings-growth ratio of 1.25 and a beta of 0.88. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. The firm had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. As a group, equities analysts predict that Teva Pharmaceutical Industries will post 2.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Roberto Mignone sold 519,000 shares of the company’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the completion of the transaction, the director now owns 981,000 shares of the company’s stock, valued at $16,706,430. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Roberto Mignone sold 519,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the sale, the director now directly owns 981,000 shares in the company, valued at $16,706,430. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now owns 45,060 shares of the company’s stock, valued at $777,285. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors have recently made changes to their positions in the business. Sequoia Financial Advisors LLC raised its position in Teva Pharmaceutical Industries by 0.7% in the second quarter. Sequoia Financial Advisors LLC now owns 111,575 shares of the company’s stock worth $1,813,000 after purchasing an additional 826 shares in the last quarter. Edmond DE Rothschild Holding S.A. lifted its position in shares of Teva Pharmaceutical Industries by 4.0% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 24,495 shares of the company’s stock worth $346,000 after buying an additional 947 shares during the period. Oppenheimer & Co. Inc. boosted its stake in Teva Pharmaceutical Industries by 9.6% in the 1st quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock valued at $191,000 after buying an additional 1,180 shares in the last quarter. QRG Capital Management Inc. grew its position in Teva Pharmaceutical Industries by 0.8% in the second quarter. QRG Capital Management Inc. now owns 144,938 shares of the company’s stock valued at $2,355,000 after acquiring an additional 1,191 shares during the period. Finally, United Services Automobile Association raised its stake in Teva Pharmaceutical Industries by 3.1% during the second quarter. United Services Automobile Association now owns 41,159 shares of the company’s stock worth $669,000 after acquiring an additional 1,249 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.